Impaired intestinal barrier function in type 2 diabetic patients measured by serum LPS, Zonulin, and IFABP

Jie-Hao Yuan,Qing-Sheng Xie,Guang-Cheng Chen,Chu-Lin Huang,Tao Yu,Qi-Kui Chen,Jie-Yao Li
DOI: https://doi.org/10.1016/j.jdiacomp.2020.107766
IF: 3.219
2021-02-01
Journal of Diabetes and its Complications
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>The epithelial tight junctions of intestine were impaired in murine model of type 2 diabetes mellitus (T2DM). The aim of this work was to investigate the alteration of intestinal barrier in T2DM patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>90 patients with T2DM and 28 healthy controls were recruited. Serum lipopolysaccharide (LPS), Zonulin, and intestinal fatty acid binding protein (IFABP) were measured by ELISA, based on which a derived permeability risk score (PRS) was calculated. Subgroup analyses were conducted based on the glycemic control (HbA1c&lt;7%, or HbA1c≥7%), the amount of chronic diabetic complications, and the use of aspirin at the time.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Serum LPS, Zonulin, and IFABP, and PRS of T2DM group were significantly higher than those of the control group (<em>p</em>&lt;0.05 for all). Serum LPS and PRS was higher in T2DM patients with poor glycemic control (both <em>p</em>&lt;0.05). Patients with more chronic complications of diabetes had higher serum LPS and IFABP, and PRS (all <em>p</em>&lt;0.05). No differences were found in these serum markers between T2DM patients being treated with aspirin or not.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Intestinal barrier function was impaired in T2DM patients. Poor glycemic control and more chronic complications of diabetes were associated with worse intestinal barrier function. Treatment with aspirin did not aggravate the impairment of intestinal barrier in T2DM patients.</p>
endocrinology & metabolism
What problem does this paper attempt to address?
This paper aims to explore the damage to the intestinal barrier function in patients with type 2 diabetes mellitus (T2DM) and evaluate the relationship between this damage and blood - glucose control, the number of chronic complications, and aspirin use. Specifically, the study assesses changes in intestinal barrier function by measuring the levels of lipopolysaccharide (LPS), zonulin, and intestinal fatty - acid - binding protein (IFABP) in serum. These indicators are considered effective markers of intestinal permeability and can reflect the integrity of the intestinal barrier. ### Research Background - **Type 2 diabetes mellitus**: Globally, the number of patients with type 2 diabetes mellitus has been increasing over the past three decades. Diabetes is not only associated with multiple complications but may also affect gastrointestinal function, especially intestinal barrier function. - **Intestinal barrier function**: The intestinal barrier is a multi - layer structure, and its main role is to defend against pathogens and toxins in the intestine. The epithelial cell layer and tight junction proteins play a key role in maintaining the integrity of the intestinal barrier. ### Research Objectives - **Evaluate the intestinal barrier function in T2DM patients**: By detecting the levels of LPS, zonulin, and IFABP in serum, evaluate whether the intestinal barrier function in T2DM patients is damaged. - **Analyze related factors**: Explore the impact of blood - glucose control levels, the number of chronic complications, and aspirin use on intestinal barrier function. ### Main Findings - **Impaired intestinal barrier function in T2DM patients**: Compared with the healthy control group, the serum levels of LPS, zonulin, and IFABP in T2DM patients were significantly increased, indicating that their intestinal barrier function was impaired. - **Relationship between blood - glucose control and intestinal barrier function**: In T2DM patients with poor blood - glucose control (HbA1c ≥7.0%), the serum levels of LPS and PRS (permeability risk score) were significantly higher than those in patients with good blood - glucose control. - **Relationship between chronic complications and intestinal barrier function**: Among T2DM patients, the more chronic complications there were, the higher the serum levels of LPS, IFABP, and PRS, indicating that chronic complications may exacerbate the damage to the intestinal barrier function. - **Effect of aspirin on intestinal barrier function**: There was no significant difference in intestinal barrier function between T2DM patients using low - dose aspirin and those not using it. ### Conclusions - **The intestinal barrier function in T2DM patients is impaired**, and this damage is related to poor blood - glucose control and an increase in the number of chronic complications. - **The use of low - dose aspirin does not exacerbate the damage to the intestinal barrier function in T2DM patients**. This paper systematically evaluates the intestinal barrier function in T2DM patients and its related factors, providing a new perspective for understanding the pathophysiological mechanism of diabetes and may provide a reference for clinical treatment.